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Abstract
New inhibitors of influenza viruses are needed to combat the potential emergence of novel
human influenza viruses. We have identified a class of small molecules that inhibit replica-
tion of influenza virus at picomolar concentrations in plaque reduction assays. The com-
pound also inhibits replication of vesicular stomatitis virus. Time of addition and dilution
experiments with influenza virus indicated that an early time point of infection was blocked
and that inhibitor 136 tightly bound to virions. Using fluorescently labeled influenza virus, in-
hibition of viral fusion to cellular membranes by blocked lipid mixing was established as the
mechanism of action for this class of inhibitors. Stabilization of the neutral pH form of hem-
agglutinin (HA) was ruled out by trypsin digestion studies in vitro and with conformation spe-
cific HA antibodies within cells. Direct visualization of 136 treated influenza virions at pH 7.5
or acidified to pH 5.0 showed that virions remain intact and that glycoproteins become disor-
ganized as expected when HA undergoes a conformational change. This suggests that ex-
posure of the fusion peptide at low pH is not inhibited but lipid mixing is inhibited, a different
mechanism than previously reported fusion inhibitors. We hypothesize that this new class
of inhibitors intercalate into the virus envelope altering the structure of the viral envelope re-
quired for fusion to cellular membranes.
Introduction
Influenza virus is an enveloped virus belonging to the Orthomyxoviridae family. Waterfowls
are the natural reservoir for most influenza A subtypes. Avian influenza viruses bind with high
affinity to α2,3 linked sialic acid containing receptors and with low affinity to α2,6 linked re-
ceptors, the converse applies for human influenza viruses [1]. Species such as pigs that contain
both α2,3 and α2,6 linked receptors allow coinfection with both human and avian influenza
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viruses [2]. Genome reassortment of coinfecting influenza viruses may result in a new influenza
virus strain containing different subtypes of HA (hemagglutinin) or NA (neuraminidase) pre-
viously unseen in humans. Humans may not have preexisting immunity to a new strain of in-
fluenza virus, so pandemics can result from genome reassortment [3]. Human cases of H5N1
have occurred sporadically since 1997 and in 2013 human cases of H7N9 have been reported
[4]. Both H5N1 and H7N9 are highly pathogenic in humans and are currently circulating in
avian reservoirs [4]. The potential of H5N1 or H7N9 viruses to jump to humans emphasize the
need for broad spectrum influenza inhibitors since vaccine development would require
months. Considering the possibility of increased resistance to neuraminidase inhibitors [5, 6],
and the threat of avian viruses to gain transmissibility among humans, new influenza inhibitors
are urgently needed.
Fusion inhibitors have been successfully used in the treatment of HIV [7]. For instance,
enfuvirtide is a peptide derived from gp41 that blocks refolding of gp41, effectively arresting fu-
sion of HIV to the cell membrane [8–10]. A peptide based inhibitor with a cholesterol moiety
attached has successfully targeted influenza virus fusion in vitro [11]. LJ001, a small molecule
able to inhibit fusion of many pseudotyped enveloped viruses, proves that small molecules can
block the fusion pathway of viruses [12]. If the influenza virus fusion pathway could be targeted
effectively by small molecule inhibitors, these inhibitors could become an important new class
of inhibitors for controlling influenza virus.
A potent inhibitor of influenza virus, (Z)-3-(bicyclo[2.2.1]heptan-2-yl)-5-((5-(4’-chlorophe-
nyl)-3-(3-(piperazin-1-yl)pentyl)furan-2-yl)-methylene)-2-thioxothiazolidin-4-one, (named
compound 136, S1 File) was developed recently [13], but the mechanism of inhibition by 136
was not clearly defined. Here we report that 136 interferes with the fusion process of influenza
virus, likely by disrupting the structure of the viral envelope necessary for fusion to cellular
membranes.
Materials and Methods
Cells and viruses
MDCK-2 cells were cultured in EMEM supplemented with 5% FBS and penicillin/streptomy-
cin. The cells were maintained in a humidified incubator at 37°C, with 5% CO2. All influenza
viruses were grown in MDCK-2 cells. Influenza virus strain X-31 (H3N2) was amplified by in-
fecting confluent MDCK-2 cells at an MOI of 0.001. After two days post-infection the superna-
tant from the cell culture was collected and subject to centrifugation at 2000 RCF to remove
cell debris and the virus in the supernatant was pelleted at 60,000 RCF for 1 hour. The virus
pellet was resuspended in 10 mMHEPES, 100 mMNaCl, pH 7.5 and further purified on a 20–
50% sucrose gradient by centrifugation for 1.75 hours at 60,000 RCF. The fractions containing
X-31 virus were collected and diluted with 10 mMHEPES, 100 mMNaCl pH 7.5 buffer. The
virus was pelleted by centrifugation at 60,000 RCF for 1 hour. The virus pellet was resuspended
at 2 mg/mL in 10 mMHEPES, 100 mMNaCl, pH 7.5 and stored at -80°C. X-31 virus was
quantitated using the Bio-Rad protein assay and BSA as a standard. A549 ATCC cells were cul-
tured as previously described [14]. Vesicular stomatitis virus (VSV) Indiana serotype was am-
plified by infecting confluent HeLa cells at an MOI of 0.001. After 1 day post-infection, the
supernatant from the cell culture was collected and subject to centrifugation at 2000 RCF to re-
move cell debris.
Antibodies
Anti-HA polyclonal antibodies have been described previously [14].
Fusion Inhibitor
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MTT assay
MDCK-2 cells were seeded at 4 to 5x104 cells/well on 96-well cell culture plate in 100 μL medi-
um containing 10% fetal bovine serum (FBS) and 1% antibiotic solution. The cells were incu-
bated overnight in a humidified 5% CO2 incubator at 37°C. Untreated cells were used as a
positive control. A set of wells treated with 1% Triton X-100 was used as 100% toxicity (nega-
tive control). The inhibitor solution was added to washed cells at a final volume of 100 μL per
well in triplicate for each condition. The cells were incubated for one day in a humidified 5%
CO2 incubator at 37°C. 15 μL of MTT substrate was added to each well (Promega) and incubat-
ed at 37°C for 1–4 hours. The reaction was stopped by adding 100 μL stop solution, following
by incubation for 5 hours at room temperature to ensure that the formazan crystal was dis-
solved. The absorbance at 570 nm was measured by a 96-well plate reader, using a reference
wavelength of 720 nm. The EC50 value was determined by locating the X-axis value corre-
sponding to one-half the maximum absorbance value.
Time of addition assay
Confluent MDCK-2 cells in 6 well plates were infected with 1000 pfu of X-31 virus and left for
1 hour at 4°C to synchronize infection. The inoculum was removed and 2 mL of EMEM was
added to each well. The samples were then placed at 37°C in a humidified incubator. At the in-
dicated time points, 20 nM of 136 or 211 was added to the wells drop wise and placed back
into the incubator. For the -1 hour sample the inoculum was incubated for 1 hour prior to in-
fecting cells. For the 0 hour sample, the inoculum was mixed with inhibitor and immediately
added to the cells prior to cold room incubation. After 15 hours the supernatant was removed,
serially diluted, and the virus concentration was tittered by plaque assay. The data shown is
representative of 3 independent experiments. Plaque assays were performed in duplicate with
error bars ± the standard deviation.
Plaque reduction assay
100 pfu of influenza virus in 100 μL of EMEMwas incubated with DMSO, or inhibitors at vari-
ous concentrations for 1 hour. All samples contained 1% DMSO. Monolayers of MDCK-2 cells
in 6 well plates were infected with 100 μL of virus samples and incubated for 1 hour at 37°C. The
inoculum was removed from the cells and EMEM supplemented with 0.8% agar and 2 μg/mL
TPCK-trypsin was added to each well. After 36 hours the cells were fixed with 4% formaldehyde,
the agar plugs removed, and the cells stained with 0.1% crystal violet. For VSV, 100 pfu of virus
in 100 μL of DMEMwas incubated with DMSO, or inhibitors at various concentrations for 1
hour. All samples contained 1% DMSO. Monolayers of HeLa cells in 6 well plates were infected
with 100 μL of virus samples and incubated for 1 hour at 37°C. The inoculum was removed from
the cells and DMEM supplemented with 0.8% agar was added to each well. After 24 hours the
cells were fixed with 4% formaldehyde, the agar plugs removed, and the cells stained with 0.1%
crystal violet. The data shown is representative of 3 independent experiments. Plaque assays
were performed in triplicate with error bars ± the standard deviation. Curve fitting, EC50 calcula-
tion, and 95% confidence intervals were calculated with GraphPad Prism 5 using the log[inhibi-
tor] vs. response equation.
Multicycle inhibition assay
Monolayers of MDCK-2 cells were infected with X-31 virus. To allow binding and internaliza-
tion of the virus to occur without exposure to 136, at 1 hour post-infection 136 (or DMSO as a
control) was added to the media at a final concentration of 5 μM, 1μM, or 200 nM. The infected
Fusion Inhibitor
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cells were incubated for 24 hours at 37°C and at 12 hours and 24 hours post-infection aliquots
were taken for plaque assay. The data shown is representative of 2 independent experiments.
Data points are the average of 2 replicates ± SD.
Preparation of fluorescently labeled virus
X-31 virus was labeled with DiD by directly adding a 5 μL aliquot of DiD Vybrant solution to
500 μL of 2 mg/mL virus sample. Labeling was performed for 2 hours at 37°C with constant
shaking. Unincorporated dye was removed by centrifugation at 60,000 x g for 30 minutes and
the pellet was resuspended in 10 mMHEPES, 100 mMNaCl, pH 7.5. Virus labeling by
DiOC18 was described previously [14].
Dilution of inhibitor-bound virus assay
1200 pfu of X-31 virus in 50 μL EMEM was incubated for 1 hour with 0.5 μL of 50 nM 136 in
DMSO or DMSO at room temperature. The sample was then diluted with EMEM to 1 mL and
incubated another hour. The remaining virus titer was determined by plaque assay as described
above except that 250 μL of sample was used to inoculate. As a control, 1200 pfu in 1 mL was
added to the same quantity of 136 and plaque assayed. The data shown is representative of 3
independent experiments. Each data point is the average of 3 replicates ± the standard
deviation.
X-31 virus binding assay
A549 cells were detached and counted, and incubated with X-31 for 1 hour at 4°C. After wash-
ing with cold medium, the cells were fixed with 4% formaldehyde at RT. After washing, the
cells were incubated in PBS containing 0.1% saponin, 1% bovine serum albumin, and HA
mouse monoclonal antibody HA1 (1:3000) (Banerjee et al., [14]) for 1 hour at room tempera-
ture. Cells were incubated with secondary anti mouse IgG-AF647 (Invitrogen) (1:2000) for
30 minutes. 10,000 cells were analyzed using FACS Canto II (BD Biosciences). Similar results
were obtained when binding was performed on non-detached A549 cells.
X-31 virus acidification, and lipid mixing assay
X-31 influenza virus was preincubated for 30 minutes with 2.5 μM 136 or 211. For the acidifi-
cation assay, A549 cells were bound with X-31 for 1 hour at 4°C in duplicate. Cells were
warmed to 37°C to allow endocytosis of the virus. After 1 hour the cells were washed with
phosphate buffered saline (PBS), harvested by trypsinization, and fixed with 4% formaldehyde.
After washing, the cells were incubated in PBS containing 0.1% saponin, 1% bovine serum al-
bumin, and HA post-acid conformation specific mouse monoclonal antibody A1 (1:1000) for
1 hour at room temperature. Cells were incubated with secondary anti mouse IgG-AF488
(Invitrogen) (1:2000) for 30 minutes. 10,000 cells were analyzed using FACS Canto II (BD Bio-
sciences). Bafilomycin A1 (BafA) was used at 50 nM as a negative control. The experiment was
repeated three times. For the lipid mixing assay, X-31 virus was labeled with R18/SP-DiOC18
[14]. A549 cells were infected for 1 hour as above. For the acid-bypass assay, trypsinized A549
cells were bound with labeled X-31 virus for 45 min on ice, and subsequently incubated for
2 min at 37°C in either pH 6.8 or pH 5.0 medium, and fixed. For FACS analysis the cells were
harvested by trypsinization and 5,000 cells were analyzed. For microscopy analysis, cells were
grown on coverslips, infected, fixed in 4% formaldehyde, and examined using a Zeiss LSM 510
confocal fluorescence microscope. BafA was used as a negative control. BafA blocks endosome
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acidification, blocking the low pH-induced conformational change of HA, and lipid mixing of
R18/SP-DiOC18 labeled influenza virus in late endosomes.
Trypsin digestion
A 50 μL aliquot of X-31 virus at 0.08 mg/mL was incubated with DMSO, 211, or 136 for 1 hour
at room temperature. Trypsin (1mg/mL final concentration) was added to the samples. Acidified
samples were acidified to pH 5.0 for 5 minutes by addition of 50 mM citrate pH 3.0 100 mM
NaCl, reneutralized with 100 μM tris pH 10.0 100 mMNaCl, and left at 37°C for 15 minutes to
allow digestion to occur. For samples that were not acidified, an equivalent volume of 10 mM
HEPES pH 7.5 100 mMNaCl was added to the samples. Trypsin digestion was stopped by addi-
tion of 2 mM 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF) for 15 minutes.
Samples were mixed with nonreducing loading buffer and loaded onto a 10% polyacrylamide gel
for SDS-PAGE. The gel was fixed and stained with the Pierce Silver Stain Kit and imaged with a
ccd based gel imager (Syngene G:box).
Negative stain electron microscopy
The 136 treated X-31 virus samples were prepared as above without addition of trypsin. 7 μL of
sample was applied to a glow discharged carbon coated grid for 30 seconds, blotted with filter
paper, stained with 7 μL of 1% phosphotungstic acid pH 7.5 for 20 seconds, and blotted again.
Samples were imaged with a FEI Tecnai 12 transmission electron microscope.
Results
Compound P25H2 was previously found to inhibit cell infection of multiple influenza virus
strains with high potency [15]. Derivatives of P25H2 were synthesized and tested for anti-influ-
enza activities in plaque reduction assays [13]. Fig. 1A shows the structure of a particularly po-
tent derivative, 136. A less potent derivative (compound 211) with a similar structure is used
for a control because it inhibits virus only at a much higher concentration than 136 (Fig. 1D).
Using X-31 virus the EC50 values of 136 and 211 were calculated by plaque reduction assays
and the results are shown in Fig. 1B and E, respectively. 136 has an EC50 value of 48 picomolar
whereas 211 has an EC50 value of 140 nanomolar, a difference of approximately 2900 fold. Pla-
que reduction assays with vesicular stomatitis virus (VSV) were also performed with 136 and
211 (Fig. 1C and F). 136 and 211 inhibited VSV with an EC50 of 130 pM and 1.2 μM, respec-
tively. An approximately three fold greater concentration of 136 is required for inhibition of
VSV as compared to X-31 virus. Table 1 summarizes the EC50 of 136 against many other influ-
enza virus strains and includes the 95% confidence interval for all virus strains tested. S1 Fig.
shows the plaque reduction assay results for the additional virus strains tested. Table 2 summa-
rizes the EC50 values of 211 and includes the 95% confidence interval for the virus strains test-
ed. Additionally, the pH of virus preparations were unaltered by 136 (S1 Table) and the
cellular toxicity (CC50) of 136 was determined to be 50 μM by a MTT assay (Fig. 2A). The se-
lectivity index of 136 is calculated to be 1x106. Because of the high potency and low cellular
toxicity of 136, it was selected for further characterization.
To assess whether multicycle influenza virus infection was inhibited by 136, infected cells were
cultured in growth media supplemented with either DMSO, 5 μM 136, 1 μM 136, or 200 nM 136
(Fig. 2B). After 12 or 24 hours of virus growth, aliquots of the media supernatant were plaque as-
sayed. At the 12 hour time point, the 5 μM, 1 μM, and 200 nM 136 samples all significantly re-
duced the number of plaques as compared with the DMSO control sample (one-way ANOVA
and Tukey post hoc test, p<0.001). After 24 hours, the 5 μM 136 sample significantly reduced the
Fusion Inhibitor
PLOS ONE | DOI:10.1371/journal.pone.0122536 March 24, 2015 5 / 15
number of plaques as compared to the DMSO control sample (one-way ANOVA and Tukey post
hoc test p<0.05). 136 inhibits single cycle and multicycle replication of influenza virus.
To determine which step of the virus replication cycle 136most effectively inhibits, time of
addition experiments were performed (Fig. 3A). For time of -1 hour the compound was prein-
cubated with virus for 1 hour prior to infection. All other time points indicate hours post-infec-
tion that the compound was added. The -1 hour time point for 136 had a 3 log reduction in
virus titer. When 136 was added at any other time point there was no inhibition as compared
to samples treated with 211 or DMSO. Inhibition of the virus at the-1 hour time point indicates
that 136may bind directly to virions and inhibit a step during virus entry into the host cell.
To confirm that 136 indeed binds to the virion, the EC95 concentration of 136 was added to
a virus sample and then diluted by 20 fold (Fig. 3B). As a positive control for exchangeable
binding, another virus sample was first diluted by 20 fold and then treated with 25 pM of 136.
Fig 1. Structure and EC50 values of inhibitors. The structures of compounds 136 (A) and 211 (D). X-31 virus plaque reduction assays were performed
using monolayers of MDCK-2 cells. For X-31 virus, the EC50 of 136 and 211was calculated to be 48 pM and 140 nM, respectively (B and E). VSV plaque
reduction assays were performed using monolayers of HeLa cells. For VSV, the EC50 of 136 and 211was calculated to be 130 pM and 1.2 μM, respectively
(C and F). Representative data are shown from 3 independent experiments. Data points are the average of 3 replicates ± SD.
doi:10.1371/journal.pone.0122536.g001
Table 1. 136 Inhibition summary.
Virus EC50 (pM) 95% Conﬁdence interval
A/Udorn/72 60.0 54.0–66.3
A/PR/8/34 27.5 25.1–30.1
A/Aichi/68 209.9 153.6–286.8
A/Victoria/3/75 126.8 98.9–162.5
A/NWS/G70C 45.3 38.7–53.0
A/X-31 48.3 35.5–65.7
B/Lee/40 64.8 53.3–78.8
VSV 127.5 102.2–159.1
doi:10.1371/journal.pone.0122536.t001
Fusion Inhibitor
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As a negative control DMSO was added and the sample was diluted by 20 fold. If 136 was to
exchangeably bind to the virion, it should diffuse into the larger volume when diluted and in-
hibit the same amount of virus as the positive control. Fig. 3B shows that even 1 hour after dilu-
tion 136 still inhibits 95% of the virus, which is consistent with its tight binding to the virus.
Fluorescent labeling of X-31 virus was quantitated in the presence of 136 and 211, as well as
DMSO as a control (Fig. 3C). The fluorescence of lipophilic labeling agent DiD was further
quenched below the control background by 136, suggesting that 136 binds in close proximity
to the membrane bound DiD.
To specifically identify the influenza virus entry step 136 inhibits, several experiments were
performed in A549 cells as described by Banerjee et. al.[14]. To determine if binding to the
host cell was inhibited by 136, X-31 virus treated with DMSO, 136, or 211 were bound to cells
in the presence of the drug for 1 hour at 4°C so internalization of the virus would not occur.
The cells were washed to remove unbound virus, and the bound virus was quantitated using a
monoclonal HA antibody and FACS analysis (Fig. 4A). 211 and 136 treated viruses bound to
host cells equally, compared to DMSO treatment. Using a low pH conformation specific anti-
body, 211 or 136 did not prevent the conformational rearrangement of HA in the endosome
(Fig. 4B). Addition of Bafilomycin A1, a potent inhibitor of endosomal vacuolar type proton
pumps, prevented the low pH conformational change of HA. X-31 viruses labeled with R18
(Octadecyl Rhodamine B Chloride) / SP-DiOC18 (3,3'-Dioctadecyl-5,5'-Di(4-Sulfophenyl)
Oxacarbocyanine) was used to study lipid mixing in the endosome (Fig. 4C). 211 did not pre-
vent dequenching of SP-DiOC18, indicating that lipid mixing occurred normally. In contrast,
cells infected with 136 treated X-31 virus showed significant decrease in dequenching of
Table 2. 211 Inhibition summary.
Virus EC50 (nM) 95% Conﬁdence interval
A/X-31 137 81–233
VSV 1240 833–1840
doi:10.1371/journal.pone.0122536.t002
Fig 2. The CC50 of 136 is 50 μM andmulticycle X-31 virus replication is inhibited. (A) Monolayers of MDCK-2 cells were used to determine the cellular
toxicity of 136 by MTT assay. The half maximal response corresponding to the CC50 concentration of 136was determined to be 50 μM. Data shown is the
average of 3 replicates ± SD. (B) Monolayers of MDCK-2 cells were used to test if 136 inhibits multicycle replication of X-31 virus. Untreated X-31 virus was
added to cells and allowed to enter host cells for 1 hour. Then 136 at a final concentration of 5 μM, 1μM, or 200 nM were added to the cells. Aliquots were
taken at 12 and 24 hours post-infection and plaque assayed. After 12 hours of X-31 virus infection, 5 μM, 1μM, and 200 nM 136 containing samples were
significantly inhibited as compared to the DMSO control (* p<0.001, one-way ANOVA and Tukey post-hoc test). After 24 hours of X-31 virus infection, 5 μM
136 is significantly inhibited as compared to the DMSO control († p<0.05. one-way ANOVA and Tukey post-hoc test). The data shown is representative of 2
independent experiments. Data points are the average of 2 replicates ± SD.
doi:10.1371/journal.pone.0122536.g002
Fusion Inhibitor
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Fig 3. Tight binding to virions. (A) MDCK-2 cells were infected with X-31 virus and treated with 136 at
various time points. For-1 hour time points the incoculum was preincubated with 136 then added to cells.
After 15 hours the virus titer was calculated by plaque assay. 136 treated X-31 at the-1 hour time point
resulted in the greatest inhibition, causing a 3 log reduction in pfu/mL (-1). Controls preincubated with DMSO
or 211 do not show inhibition (DMSO-1, and 211–1). At all other time points when 136was added (0, 1, 2, 3,
5, 7 hrs) no significant inhibition was observed. (B) 136 is tightly bound to X-31 virus as demonstrated by
insensitivity to dilution. As a negative control DMSO was added to virus and diluted 20 fold so that 300 pfu
would remain (DMSO). The EC95 concentration (500 pM) of 136was added to virus and diluted 20 fold (500
pM 136 dil to 25 pM). As a positive control virus was first diluted 20 fold and then 25 pM of 136was added. If
binding of 136was loose, both samples with 136 should cause inhibition to the same extent since 136would
diffuse into the larger volume (* p<0.001, one-way ANOVA and Tukey post-hoc test). (C) X-31 virus was
Fusion Inhibitor
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SP-DiOC18, as detected by FACS (Fig. 4C) and fluorescence microscopy (Fig. 4E). This indi-
cated that 136 blocks lipid mixing at the endosome. Similar results were obtained when X-31
virus was fused at the plasma membrane using the acid bypass assay (Fig. 4D).
To further confirm that the HA conformational change at low pH is not inhibited by 136,
we performed in vitro trypsin susceptibility studies. At a pH of 5.6 or lower, HA unfolds and
exposes trypsin sensitive sites of HA that are not present at neutral pH [16]. As seen in Fig. 5A,
the controls at pH 5.0 incubated with DMSO (lane 2) or 211 (lane 6) show complete degrada-
tion of HA by trypsin and the appearance of an HA fragment band. Acidified viruses treated
with increasing concentrations of 136 also show complete degradation of HA by trypsin (lanes
3–5), indicating no inhibition of the HA conformational change. Samples at pH 5.0 but left un-
treated with trypsin (lanes 7–9) show no degradation of HA and neither does a control sample
left at pH 7.5 without trypsin treatment (lane 10). All samples left at pH 7.5 with trypsin treat-
ment (lanes 11–13) show no degradation of HA since trypsin is unable to access the cleavage
sites without the conformational change of HA. HA is not destabilized by 136 at pH 7.5. If HA
was destabilized, we would expect HA to be degraded at pH 7.5. Additionally, NP and M1 are
intact in all samples indicating that pores large enough for trypsin to penetrate into the virus
are not present and that the virus remains intact when treated with 136. Negative stained elec-
tron microscopy was used to directly visualize 136 treated X-31 virions at pH 7.5 and 5.0
(Fig. 5B and C). The virions appeared identical to DMSO or 211 treated virions (data not
shown). 136 treated virions are intact with organized HA spikes at pH 7.5. At pH 5.0 the virion
remains intact and the HA spikes appear more disordered, consistent with a conformational
change of HA.
Discussion
The fusion pathway of influenza virus has been extensively studied but some uncertainties still
exist. After binding to cell surface receptors, influenza virus is internalized either by clathrin
mediated endocytosis or macropinocytosis [17]. During endosomal maturation, low intralum-
inal pH triggers an irreversible conformational change of HA, exposing the fusion peptide
[18, 19]. The unveiled fusion peptide inserts itself between bilayers of the endosomal mem-
brane and HA refolds into a six-helix bundle, resulting in fusion of the viral membrane to the
endosomal membrane [20]. This mechanism is common for all subtypes of influenza A virus
and influenza B virus. Our new inhibitor 136 targets this mechanism and has potent antiviral
activities against a large variety of influenza viruses, as well as VSV. The results of our time of
addition, dilution of inhibitor bound virus, and imaging indicate that the inhibitor prevents
viral fusion with cellular membranes. Trypsin sensitivity studies and electron microscopy fur-
ther revealed that the inhibitor does not perforate the viral envelope, stabilize HA, or prevent
the low pH induced conformational change of HA.
In vitro studies of 136 treated influenza virus suggests that the structure of the viral envelope
was changed by binding of 136 to the virion. The baseline fluorescence of DiD labeled virions
was further reduced by treatment with 136 but not 211 or DMSO, suggesting that 136 interca-
lates in the membrane of the virus in close proximity to DiD (Fig. 3C). Our experiments clearly
show that 136 blocks lipid mixing of the influenza virus envelope with the plasma membrane
labeled with the fluorescent lipophilic dye DiD. DMSO, 211, or 136were added to the labeled X-31 samples
and the quenching of DiD was monitored using a spectrofluorometer at λEX = 644 nm/λEM = 665 nm. The
fluorescence signal was the same for DMSO and 211 treated samples but the fluorescence signal was
significantly quenched by 136 (* p<0.001, one-way ANOVA and Tukey post-hoc test). The data shown is
representative of 2 independent experiments. Data points are the average of 3 replicates ± SD.
doi:10.1371/journal.pone.0122536.g003
Fusion Inhibitor
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Fig 4. Lipid mixing is blocked in 136 treated X-31 virus in A549 cells. (A) Virus binding to A549 cells. X-
31 virus was treated with 211 or 136 and allowed to bind to A549 cells in the cold for 60 min. A549 cells were
fixed and stained with a monoclonal HA antibody and analyzed by FACS. (B) X-31 virus was treated with 211
or 136 and allowed to enter A549 cells for 60 min. Cells were fixed and stained for the acidic form of HA. 50
nM Bafilomycin A1 (BafA) was used to block endosome acidification. (C) Lipid mixing in endosomes of A549
cells. X-31 virus was treated with 211 or 136 and allowed to enter cells for 60 min. Cells were fixed and
analyzed for DiOC18 dequenching (Student’s t test; p<0.001). (D) Lipid mixing after acid-bypass fusion at the
plasmamembrane. X-31 virus was treated with 211 or 136, bound to A549 cells in the cold for 60 min,
followed by induction of fusion in warm pH 5.0 (or pH 6.8 for control) medium for 2 min, and fixed. Cells were
analyzed for DiOC18 dequenching (Student’s t test; p<0.001). (E) Lipid mixing in endosomes of A549 cells.
X-31 virus was treated with 211 or 136 and allowed to enter cells for 60 min. Cells were fixed and analyzed by
fluorescence microscopy. The data shown are representative of 3 independent experiments performed in
duplicate ± SD. Broken lines depict the outline of cells and nuclei. Bars; 10μm.
doi:10.1371/journal.pone.0122536.g004
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Fig 5. The HA conformational change is not inhibited. (A) X-31 virus was incubated with DMSO (D)
50 nM, 360 nM or 1,060 nM 136 (1) or 1,060 nM 211 (2). Samples were acidified to pH 5.0 and reneutralized
(+) or left at pH 7.5 (-). Trypsin (Tryp) was added to cleave unfolded HA (+), or an equal volume of buffer for
samples without trypsin was added (-). Trypsin digestion was stopped by addition of AEBSF. The samples
were mixed with non-reducing loading buffer and loaded onto a 10% polyacrylamide gel for SDS-PAGE.
Lane 1: ladder. Lane 2: HA is degraded by trypsin at pH 5.0. Lanes 3–5: HA is degraded by trypsin at pH 5.0
with 136 treatment, indicating HA is still able to conformationally change. Lane 6: HA is degraded by trypsin at
pH 5.0 and 211 treatment. Lanes 7–9: HA is not degraded if trypsin is absent at pH 5.0. Lane 10: HA is not
degraded if trypsin is absent at pH 7.5. Lanes 11–13: HA is not degraded by trypsin at neutral pH. Lane 14:
trpsin only. 50 nM, 360 nM and 1,060 nM 136 correspond to the EC50, EC90 and the EC99, respectively, for
this experiment. Lanes 5, 8, 12, and 14 contain 1,060 nM 136. HA: hemagglutinin, NP: nucleoprotein, F:
fragment, M1: matrix 1 protein, T: trypsin, Cmpd: compound. Representative gel from 3 independent
experiments. (B and C) Representative micrographs of X-31 virus treated with 136 are shown. The virus
remains intact with organized HA spikes at pH 7.5 (B) but at pH 5.0 the spikes become disorganized
consistent with a conformational change (C). Scale bars: 100 nm.
doi:10.1371/journal.pone.0122536.g005
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and the late endosomal membrane of A549 cells (Fig. 4C and D). It is possible that integrity of
the viral envelope is required for successful viral fusion with cellular membranes. Changes of
viral envelope properties induced by 136may result in the arrest of complete
membrane fusion.
A recent paper described the mechanism of inhibition of compound LJ001 which contains a
portion structurally similar to 136 [21]. The authors demonstrate that LJ001 and active analogs
bind to lipid bilayers [21]. In the presence of light they produce reactive oxygen species that
can react with the unsaturated fatty acid chains of phospholipids thus disrupting the biophysi-
cal properties of the membrane critical to the fusion process [21]. When 136 in an oxygen at-
mosphere was subject to UV irradiation for 12 hours, no changes in its NMR profile was
observed (S2 Fig.), suggesting high stability of 136. This result is consistent with 136 tightly
binding to the virion membrane. We hypothesize that binding of 136 alters the structure of the
viral envelope preventing it from fusing with cellular membranes.
A number of other influenza virus entry inhibitors have been reported (recently reviewed in
[22]). Attachment of the virus to the host cell is the first step in the entry pathway. Peptides
and small molecules that mimic sialic acid have been developed that bind to the receptor bind-
ing pocket of HA thus preventing attachment and internalization of the virus [23–25]. Addi-
tionally, small molecules capable of binding to pockets in HA prevent the low pH
conformational rearrangement of HA necessary for fusion [26–33]. Compound 136 does not
block cell binding (Fig. 4A), or stabilize the low pH form of HA (Fig. 5), but blocks viral entry
at the lipid mixing step (Fig. 4C and D).
Current influenza virus inhibitors target viral proteins that are genetically encoded by the
virus. However, influenza virus can quickly gain resistant mutations [5, 34, 35]. The optimal
strategy would be to target properties of the virus that are not dominantly genetically encoded,
reducing the probability of the virus to gain quick resistance through mutation [36]. Rigid am-
phipathic fusion inhibitors (RAFIs) were developed to inhibit several enveloped viruses by
binding to the virion membrane [37]. Resistant mutants of HSV1 could not be generated
against RAFIs [37]. Similarly, 136 can inhibit influenza virus as well as VSV by binding to the
viral envelope and blocking the virus from fusing with cellular membranes. As with RAFIs,
clearly resistant mutants to 136 could not be selected by repeated passages at sublethal concen-
trations or by selecting a preexisting mutant from a genetically diverse high titer virus stock
(data not shown). The binding of 136 to Influenza virions is likely related to the transmem-
brane domain of HA and the unique lipid composition in the viral envelope, which may still
change when substantial mutations occur in viral proteins that determine virus assembly and
budding. However, such mutations would take a long period of time to develop and the mutant
virus may lose its fitness to become less infectious.
Supporting Information
S1 Fig. The plaque reduction assays of 136 against many different influenza virus strains.
Influenza virus plaque reduction assays were performed using monolayers of MDCK-2 cells.
Representative data are shown from 3 independent experiments. Data points are the average of
2 replicates ± SD.
(TIF)
S2 Fig. 136 NMR profiles. 1-D NMR profiles of 136 before (A) and after (B) 12 hours of UV
irradiation and oxygen exposure appear identical, suggesting high stability of 136.
(TIF)
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S1 File. Synthesis of compounds 136 and 211. The detailed chemical synthesis protocols for
136 and 211.
(DOCX)
S1 Table. 136 does not alter the pH of virus preparations. The pH of 100 pfu/mL virus prepa-
rations. 3 independent experiments are shown.
(TIF)
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